<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01750242</url>
  </required_header>
  <id_info>
    <org_study_id>1669</org_study_id>
    <nct_id>NCT01750242</nct_id>
  </id_info>
  <brief_title>Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study</brief_title>
  <acronym>DBS</acronym>
  <official_title>OPTIVISE Map Concordance Study in DBS for Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedtronicNeuro</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedtronicNeuro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate DBS device settings and match with the features of the DBS care management
      software.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study done on Parkinson disease subjects who have received the DBS system implanted
      in their subthalamic nucleus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To Characterize the Percentage of Leads in Which the Target Map and the Clinically-derived Activation Map Overlap</measure>
    <time_frame>18 months</time_frame>
    <description>The one-sided 95% exact binomial lower confidence bound of the proportion was calculated from subjects with readable images enrolled in the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional Study Measure on Unified Parkinson's Disease Rating Scale (UPDRS) III Scores</measure>
    <time_frame>Change from baseline to 18 months</time_frame>
    <description>The summary of UPDRS III medication off score at baseline and the UPDRS III stimulation on/medication off score at follow-up and the change from baseline to 18 months. The UPRS III has a range of 0 - 108.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's disease Subjects</arm_group_label>
    <description>Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system in the subthalamic nucleus (STN).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic DBS system</intervention_name>
    <description>Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.</description>
    <arm_group_label>Parkinson's disease Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Parkinson's disease patients who have been implanted with the DBS system
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with Medtronic Deep Brain Stimulation therapy for idiopathic levodopa
             responsive Parkinson's Disease

          -  Patient who has had lead placement in the Subthalamic nucleus

          -  Patient with pre-op MRI available

          -  Patient with post-op CT scan available showing placement of the lead

          -  Patient who has documented improvement of at least 35% on UPDRS III scores from
             baseline preoperative off medication state compared to post DBS implant stimulation
             on/medications off

        Exclusion Criteria:

          -  Patient who has had clinically significant persistent stimulation related adverse
             effects

          -  Patient who has evidence of lead migration without lead revision

          -  Patient with other brain malformations that would make it difficult to process images
             (ablative surgery in the basal ganglia, resective surgery, brain tumor)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Pahwa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melissa Houser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Clinic Division of Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Clinic, Division of Neurology</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2012</study_first_posted>
  <results_first_submitted>March 21, 2014</results_first_submitted>
  <results_first_submitted_qc>September 10, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 17, 2014</results_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Following enrollment but prior to analysis, MRIs were evaluated for readability. Those unreadable were excluded from analysis (N=3).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PD Patients Implanted With DBS System</title>
          <description>Subjects implanted with Medtronic DBS system for the treatment of Parkinson's disease with leads in the subthalamic nucleus who consented for the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Readable Images</title>
              <participants_list>
                <participants group_id="P1" count="20">Subjects with readable images were analyzed and there were 3 subjects with unreadable images.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unreadable Images</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per protocol</population>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Advanced Parkinson's Disease</title>
          <description>Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system and with documented improvement of at least 35% on UPDRS III from baseline preoperative off medication to post-DBS implant stimulation on/medication off.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>UPDRS III scores at baseline</title>
          <description>Patients with documented improvement of UPDRS III scores of at least 35% were included in the study. A higher score means more motor dysfunction. The score can range from 0 -108.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.4" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Characterize the Percentage of Leads in Which the Target Map and the Clinically-derived Activation Map Overlap</title>
        <description>The one-sided 95% exact binomial lower confidence bound of the proportion was calculated from subjects with readable images enrolled in the study.</description>
        <time_frame>18 months</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PD Patients Implanted With DBS System</title>
            <description>Subjects implanted with Medtronic DBS system for the treatment of Parkinson's disease with leads in the subthalamic nucleus and with readable images.</description>
          </group>
        </group_list>
        <measure>
          <title>To Characterize the Percentage of Leads in Which the Target Map and the Clinically-derived Activation Map Overlap</title>
          <description>The one-sided 95% exact binomial lower confidence bound of the proportion was calculated from subjects with readable images enrolled in the study.</description>
          <population>Per Protocol</population>
          <units>percentage of leads</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>leads</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A 95% lower confidence bound was calculated on the percentage of leads where an overlap existed. A subject may have 1 or 2 leads included in the analysis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>% of leads</param_type>
            <param_value>86.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>73.7</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Additional Study Measure on Unified Parkinson's Disease Rating Scale (UPDRS) III Scores</title>
        <description>The summary of UPDRS III medication off score at baseline and the UPDRS III stimulation on/medication off score at follow-up and the change from baseline to 18 months. The UPRS III has a range of 0 - 108.</description>
        <time_frame>Change from baseline to 18 months</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Advanced Parkinson's Disease</title>
            <description>Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system and with documented improvement of at least 35% on UPDRS III from baseline preoperative off medication to post-DBS implant stimulation on/medication off.</description>
          </group>
        </group_list>
        <measure>
          <title>Additional Study Measure on Unified Parkinson's Disease Rating Scale (UPDRS) III Scores</title>
          <description>The summary of UPDRS III medication off score at baseline and the UPDRS III stimulation on/medication off score at follow-up and the change from baseline to 18 months. The UPRS III has a range of 0 - 108.</description>
          <population>Per protocol</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Summary statistics on the UPDRS III score. A higher score is more motor dysfunction.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.5</ci_lower_limit>
            <ci_upper_limit>-18.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No safety data collected</time_frame>
      <desc>The protocol for the study did not include safety data collection</desc>
      <group_list>
        <group group_id="E1">
          <title>Subjects With Advanced Parkinson's Disease</title>
          <description>The study protocol did not require safety data to be collected for the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie Salisbury</name_or_title>
      <organization>Medtronic Neuromodulation</organization>
      <phone>763-526-8096</phone>
      <email>stephanie.salisbury@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

